Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Reuters NewMedia - Thursday November 8, 2001
Trimeris, which is developing an anti-HIV drug called T-20 with Swiss-based Roche Holding , said its net loss widened to $15 million, or 86 cents per share, from $8.5 million, or 54 cents per share, a year earlier.
Trimeris attributed the wider loss to expenses incurred in the quarter for ongoing Phase III clinical trials of T-20, initiated in fourth quarter 2000, as well as production of drug material for future clinical trials.
T-20 is the first of a new class of anti-HIV drugs called fusion inhibitors, which work by preventing the virus that causes AIDS from getting into the cells it attacks.
The drug could save the lives of thousands of people who fail to respond to conventional therapy. But its big drawback is that patients have to inject themselves, rather than take a pill, since the drug would be destroyed by digestive enzymes.
"Together with our partner Roche, we remain on track to submit T-20 for regulatory approval in 2002," Trimeris said in a release.
011108
RE011115
Copyright © 2001 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .